Ascendis Pharma's YORVIPATH Now Commercially Available In The U.S. For The Treatment Of Hypoparathyroidism In Adults
Ascendis Pharma's YORVIPATH Now Commercially Available In The U.S. For The Treatment Of Hypoparathyroidism In Adults
Ascendis Pharma的YORVIPATH現在在美國正式推出，用於治療成人低甲狀旁腺功能減退症。
Ascendis Pharma A/S (NASDAQ:ASND) today announced that YORVIPATH (palopegteriparatide; developed as TransCon PTH) is now commercially available by prescription in the United States. YORVIPATH is a prodrug of parathyroid hormone (PTH [1-34]), administered once-daily, designed to provide continuous exposure to active PTH over the 24-hour dosing period. It is the first and only medicine approved by the U.S. Food & Drug Administration (FDA) for the treatment of hypoparathyroidism in adults.
Ascendis Pharma A/S（納斯達克:ASND）今日宣佈，YORVIPATH（帕洛帕肽；開發作爲TransCon PTH）現在在美國可以通過處方獲得。YORVIPATH是甲狀旁腺激素（PTH [1-34]）的前藥，按需每日一次給藥，旨在提供對活性PTH的持續暴露，覆蓋24小時的給藥週期。它是美國食品和藥物管理局（FDA）批准的第一個也是唯一一個用於治療成人低甲狀旁腺激素症的藥物。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間